Bow, E.J., Vanness, D.J., Slavin, M., Cordonnier, C., Cornely, O.A., Marks, D.I., . . . Schlamm, H. (2015). Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. BMC Infectious Diseases, 15, 128-015-0855-6.
STUDY PURPOSE: To compare clinical trials examining outcomes with use of oral antifungal agents for prophylaxis in patients undergoing hematopoietic cell transplantation
PHASE OF CARE: Transition phase after active treatment
Network meta-analysis using Bayesian statistical techniques were used. Results showed that voriconazole was the agent most likely to reduce incidence of overall probable or proven invasive fungal infection at 180 days post-transplantation. Mold-active agents voriconazole, itraconazole, and posaconazole were overall more likely to be effective than fluconazole as primary antifungal prophylaxis.
Findings suggest that primary antifungal prophylaxis with mold-active agents are more effective for patients undergoing allogeneic HCT.
Primary antifungal prophylaxis with mold-active agents may be preferred to reduce probable or proven invasive fungal infections. Aspergillus tends to predominate invasive fungal infections in this group of patients. There is limited data directly comparing the various mold-active agents.
Bow, E.J., Laverdiere, M., Lussier, N., Rotstein, C., Cheang, M.S. & Ioannou, S. (2002). Antifungal prophylaxis for severely neutropenic chemotherapy recipients: A meta analysis of randomized-controlled clinical trials. Cancer, 94, 3230–3246.
The evaluated treatment was antifungal prophylaxis with azoles (fluconazole, itraconazole, ketoconazole, and miconazole) or an amphotericin B formulation compared with placebo or no prophylaxis controls.
The search used MEDLINE and EMBASE (1966–2000); additional studies were identified from bibliographies/reference lists of articles, topical reviews, and information from the pharmaceutical industry and investigators in the field.
38 randomized, controlled trials
7,014 patients who received cytotoxic therapy for acute leukemia or hematopoietic stem cell transplantation (HSCT) sufficient to result in neutropenia (an absolute neutrophil count [ANC] of less than 1,000) lasting one week or more.
In severely neutropenic patients (ANC less than 1,000 for a week or more), antifungal prophylaxis reduced the use of:
In subgroup analyses, superficial fungal infections were not reduced for:
However, superficial fungal infections were reduced in HSCT recipients on azoles.
In subgroup analyses, fluconazole was more effective than itraconazole or low-dose amphotericin B formulations to prevent superficial fungal infections.
In subgroup analyses, a reduction in fungal infection-related mortality was not observed in:
There was a reduction in fungal infection-related mortality in trials using fluconazole for antifungal prophylaxis.
Antifungal prophylaxis did not affect:
Bourke, L., Thompson, G., Gibson, D. J., Daley, A., Crank, H., Adam, I., . . . Saxton, J. (2011). Pragmatic lifestyle intervention in patients recovering from colon cancer: a randomized controlled pilot study. Archives of Physical Medicine and Rehabilitation, 92, 749–755.
To investigate the feasibility of an intervention aimed at increasing exercise participation and improving dietary behavior in survivors of colon cancer and obtain preliminary data on the effect of the intervention on fatigue, exercise, and dietary outcomes.
Patients were randomly assigned to intervention or standard care control groups. The 12-week intervention included supervised and home-based exercise and dietary advice. During the first six weeks, the experimental group attended two group supervised exercise sessions of 30 minutes of aerobic exercise. Participants were asked to continue the same time of activities at home once a week during the same period and were asked to keep an exercise log. During the last six weeks, participants attended a supervised session once a week and were to perform two weekly home-based exercise sessions. Participants were given a dietary advice information pack and periodically attended healthy eating seminars encouraging reduction in saturated fat, increased fiber intake, reduction in refined carbohydrates, and limited alcohol intake.
Patients were undergoing the transition phase after initial treatment.
This was a randomized, controlled trial that was single-blinded for some outcome measures.
There was an overall 90% attendance rate at supervised exercise sessions and a 77% attendance rate at dietary seminars. Of those in the intervention group, 66.6% returned exercise logs, and among these, there was a 94% rate of adherence to independent aerobic exercise for 25 to 30 minutes. There was no significant difference between groups in exercise behavior. Fatigue scores improved significantly in the intervention group (p = 0.005) compared to controls. There was a significant increase in dietary fiber intake (p = 0.044), with no other differences in dietary habits. Compared to controls, there were significant improvements in chair sit to stand performance (p = 0.003) and aerobic exercise tolerance (p = 0.01).
Combined supervised group and home-based individual exercise with dietary education was shown to be feasible and demonstrated preliminary positive effects on fatigue and dietary fiber intake.
Findings suggested that an intervention combining some group supervised exercise and some home-based exercise is feasible and can be effective in reducing fatigue. Further research in this area is warranted as researchers attempt to determine the most effective ways to provide exercise interventions that patients will adhere to. The combination of some group periodic supervised sessions may improve patient motivations to adhere to a program, given the relatively low dropout rate seen here. This study was performed after completion of cancer treatment.
Botrel, T.E., Clark, O.A., Clark, L., Paladini, L., Faleiros, E., & Pegoretti, B. (2010). Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: Systematic review and meta-analysis. Supportive Care in Cancer, 19, 823–832.
To analyze randomized, controlled trials (RCTs) comparing a single IV palonosetron dose to other serotonin antagonists for prevention of chemotherapy-induced nausea and vomiting (CINV)
Databases searched were Embase, LILACS, MEDLINE, SCI, CENTRAL, National Cancer Institute Clinical Trials service, Clinical Trials Register of Trials Central, American Society of Clinical Oncology, and American Society of Hematology and European Society for Medical Oncology abstracts.
Search keywords were palonosetron, random, chemotherapy, clinical trial, meta-analysis, practice guideline, randomized controlled trial, and review.
Studies were included in the review if they
Initially, 324 references were identified. Five trials were used for final analysis. Two independent reviewers extracted study data and evaluated study quality and risk of bias. No specific methodology for this was described.
Boström, A., Lindman, H., Swartling, C., Berne, B., & Bergh, J. (2001). Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis: Results from a double-blind, randomized study. Radiotherapy and Oncology, 59, 257–265.
To determine if use of mometasone furoate (MMF), a corticosteroid cream could reduce intensity of erythema in acute radiation dermatitis
Patients were randomized to receive tubes of either MMF cream 0.1% or an emollient cream as a placebo control. Patients were instructed to apply the cream on the irradiated area twice a week up to 24 Gy and then once daily for the rest of treatment and three weeks after completion of radiation therapy. All patients in both study groups also applied the emollient cream over the radiated area once daily throughout the entire study period.
The study took place in Uppsala, Sweden.
The study used a randomized double-blind controlled design.
MMF patients showed less pronounced erythema, less itching and less burning than emollient group. MMF may provide a benefit.
Bortolussi, R., Zotti, P., Matovic, M., Morabito, A., Bertuzzi, C., Caserta, M., . . . Roscetti, A. (2016). A phase II study on the efficacy and safety of procedural analgesia with fentanyl buccal tablet in cancer patients for the placement of indwelling central venous access systems. Supportive Care in Cancer, 24, 1537–1543.
To determine the effectiveness of using fentanyl buccal tablets (FBT) to reduce pain related to placing indwelling vascular access ports in opioid-naïve patients with cancer
Patients were assessed on anxiety and pain preoperatively. Ten minutes prior to the procedure, 100 mcg FBT was administered. Patients were assessed postoperatively on pain during the procedure. Side effects and symptoms were monitored during, after, and four hours after the procedure. Those with anesthesia-related nausea received one metoclopramide tablet one hour prior to the procedure, and those with extreme pain during the procedure received rescue therapy of 30 mg ketorolac or 20 drops of tramadol if allergic to NSAIDS/ASA.
Use of FBT pre-procedure to reduce pain perception is a plausible intervention for pain control in those receiving a port but is not without side effects. Further consideration to prevent or ameliorate side effects and further studies with a larger population should be considered.
Nursing would need to be prepared for management of side effects and potential fall risk post-procedure. Side effects could require restructuring the postoperative environment to meet the needs of the patients or require follow-up beyond four hours.
Borjeson, S., Hursti, T.J., Tishelman, C., Peterson, C., & Steineck, G. (2002). Treatment of nausea and emesis during cancer chemotherapy: Discrepancies between antiemetic effect and well-being. Journal of Pain and Symptom Management, 24, 345–358.
To evaluate the relationship between antiemetic effect and well being over four different antiemetic treatment strategies
This study was conducted in the greater Stockholm, Sweden, area, with two gynecologic oncology wards.
Patients were randomly admitted to one of the two hospital wards for the study. Study II was a randomized, double-blind trial on the same hospital wards.
Borinstein, S.C., Pollard, J., Winter, L., & Hawkins, D.S. (2009). Pegfilgrastim for prevention of chemotherapy-associated neutropenia in pediatric patients with solid tumors. Pediatric Blood and Cancer, 53, 375–378.
To provide information about organizational experience with use of pegfilgrastim following dose intensive chemotherapy for solid tumors in pediatric patients with cancer.
Medical records of patients receiving myelosuppressive therapy supported with pegfilgrastim were reviewed (cases from 2007–2008). By protocol, pegfilgrastim was given in the outpatient clinic by subcutaneous injection at 0.1 mg/kg to a maximum does of 6 mg 24–48 hours after completion of chemotherapy. Complete blood counts (CBCs) were routinely monitored every 7–10 days during therapy cycles, then every 2–5 days until neutrophil recovery. Analysis was limited to the first four courses of chemotherapy.
Retrospective descriptive
There were no significant adverse effects observed with pegfilgrastim. Leukocytosis was observed in 73% of patients, with no adverse sequelae. Severe neutropenia occurred in 57% of chemotherapy courses, and febrile neutropenia was seen in 28% of courses. Course delay occurred in 9% of courses, with a mean duration of two days of delay.
This report provides evidence regarding the safety and efficacy of pegfilgrastim among a pediatric cancer population.
Findings suggest that pegfilgrastim is effective and can be safety given to pediatric patients.
Bordin, N.A., Guerreiro Godoy Mde, F., & Pereira de Godoy, J.M. (2009). Mechanical lymphatic drainage in the treatment of arm lymphedema. Indian Journal of Cancer, 46(4), 337–339.
To evaluate a method of mechanical lymphatic drainage using the RAGodoy apparatus
Lymphedema was confirmed with lymphoscintigraph and volumetry and defined as a difference in arm volumes of more than 200 ml. Patients had a one-hour session with the RAGodoy mechanical apparatus, which provides 15–25 elbow bending and stretching exercises per minute. Pre- and post-treatment volumetry was taken.
The study took place at a single outpatient site in Brazil.
The study used a prospective trial design.
The reduction in the volume was an average of 59.2 ml (p < 0.001). In two cases, there was an increase in volume with the intervention. In the remaining 23, there was a decrease in volume. It appeared that for those where there was an increase, the patients did not fully allow the device to passively work.
Passive mechanical exercise for lymphatic drainage may be helpful in the management of lymphedema
Use of a device for provision of passive limb exercise in the management of lymphedema requires further study.
Bordeleau, L., Pritchard, K., Goodwin, P., & Loprinzi, C. (2007). Therapeutic options for the management of hot flashes in breast cancer survivors: An evidence-based review. Clinical Therapeutics, 29, 230–241.
STUDY PURPOSE: To explore the effectiveness of pharmalogic and nonpharmalogic agents in treating hot flashes in breast cancer survivors
TYPE OF STUDY: Systematic review
PHASE OF CARE: Transition phase after active treatment
APPLICATIONS: Elder care
CAM therapies and vitamin E appear to have some effect, but data are limited. Gabapentin and some of the newer antidepressants were the most effective, with some side effects. These studies had small to moderate sample sizes, which makes overall effectiveness difficult to establish.
Nurses need to know the negative effects of hormonal agents on safety. Nonpharmacologic agents, such as soy phytoestrogens, black cohosh, and vitamin E, appear to be ineffective and limited because of the methodological limitations of studies. Gabapentin and some of the newer antidepressants were the most effective but still have side effects.